MedTrace Logo

B-cell Immunity to Influenza (SLVP017)- Year 5, 2013

NCT03020537 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2018-06-06

Study results available
· View outcomes & findings →

Summary

In this exploratory study, investigators will be looking at immune response differences between age groups and between the two different vaccines given to identical twins and vaccine-naive young adults.

Conditions

Interventions

BIOLOGICAL

Fluzone

Fluzone (Influenza Virus Vaccine) Suspension for Intramuscular Injection 2013-2014 Formula.

Sponsors & Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • Stanford University

    lead OTHER

Principal Investigators

  • Cornelia Dekker, MD · Stanford University

  • Harry Greenberg, MD · Stanford University

  • Stephen Quake, PhD · Stanford University

  • Xiaosong He, PhD · Stanford University

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Year
Max Age
30 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-10-31
Primary Completion
2013-12-31
Completion
2013-12-31

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03020537 on ClinicalTrials.gov